Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cogstate Ltd ( (AU:CGS) ) has issued an announcement.
Cogstate Ltd has announced an extension of its share buyback program, initially set to conclude on November 10, 2025. This move indicates the company’s ongoing commitment to managing its capital structure and potentially enhancing shareholder value. By extending the buyback, Cogstate may be aiming to bolster its market position and signal confidence in its financial health, which could have positive implications for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners in delivering electronic clinical outcome assessment solutions. Cogstate’s offerings include quality assurance services for study endpoints, advanced analytics, and scientific consulting, serving biopharmaceutical companies, academic institutions, physicians, and patients worldwide.
YTD Price Performance: 161.37%
Average Trading Volume: 252,584
Technical Sentiment Signal: Buy
Current Market Cap: A$463.4M
For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.